000167442 001__ 167442
000167442 005__ 20240229133539.0
000167442 0247_ $$2doi$$a10.21037/tlcr-20-727
000167442 0247_ $$2pmid$$apmid:33569307
000167442 0247_ $$2pmc$$apmc:PMC7867751
000167442 0247_ $$2ISSN$$a2218-6751
000167442 0247_ $$2ISSN$$a2226-4477
000167442 037__ $$aDKFZ-2021-00346
000167442 041__ $$aeng
000167442 082__ $$a610
000167442 1001_ $$0P:(DE-He78)5b69eb65801a144c299d2aee312aefa8$$aGonzalez Maldonado, Sandra$$b0$$eFirst author$$udkfz
000167442 245__ $$aCan autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI).
000167442 260__ $$a[S.l.]$$c2021
000167442 3367_ $$2DRIVER$$aarticle
000167442 3367_ $$2DataCite$$aOutput Types/Journal article
000167442 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1615467731_15614
000167442 3367_ $$2BibTeX$$aARTICLE
000167442 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167442 3367_ $$00$$2EndNote$$aJournal Article
000167442 500__ $$a#EA:C020#LA:C020#
000167442 520__ $$aTumor-associated autoantibodies are considered promising markers for early lung cancer detection; so far, however, their capacity to detect cancer has been tested mostly in a clinical context, but not in population screening settings. This study evaluates the early detection accuracy, in terms of sensitivity and specificity, of EarlyCDT®-Lung-a test panel of seven tumor-associated autoantibodies optimized for lung cancer detection-using blood samples originally collected as part of the German Lung Cancer Screening Intervention Trial.The EarlyCDT®-Lung test was performed for all participants with lung cancer detected via low-dose computed tomography and with available blood samples taken at detection, and for 180 retrospectively selected cancer-free participants at the end of follow-up: 90 randomly selected from among all cancer-free participants (baseline controls) and 90 randomly selected from among cancer-free participants with suspicious imaging findings (suspicious nodules controls). Sensitivity and specificity of lung cancer detection were estimated in the case group and the two control groups, respectively.In the case group, the test panel showed a sensitivity of only 13.0% (95% CI: 4.9-26.3%). Specificity was estimated at 88.9% (95% CI: 80.5-94.5%) in the baseline control group, and 91.1% (95% CI: 83.2-96.1%) among controls presenting CT-detected nodules.The test panel showed insufficient sensitivity for detecting lung cancer at an equally early stage as with low-dose computed tomography screening.
000167442 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167442 588__ $$aDataset connected to CrossRef, PubMed,
000167442 650_7 $$2Other$$aLung cancer screening
000167442 650_7 $$2Other$$aautoantibody test
000167442 650_7 $$2Other$$aearly detection
000167442 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b1$$udkfz
000167442 7001_ $$0P:(DE-He78)474d6825dc4c767e7164354e6fe8c885$$aMotsch, Erna$$b2$$udkfz
000167442 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b3$$udkfz
000167442 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b4$$eLast author$$udkfz
000167442 773__ $$0PERI:(DE-600)2754335-3$$a10.21037/tlcr-20-727$$gVol. 10, no. 1, p. 233 - 242$$n1$$p233 - 242$$tTranslational Lung Cancer Research$$v10$$x2226-4477$$y2021
000167442 909CO $$ooai:inrepo02.dkfz.de:167442$$pVDB
000167442 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5b69eb65801a144c299d2aee312aefa8$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000167442 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000167442 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)474d6825dc4c767e7164354e6fe8c885$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000167442 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000167442 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000167442 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167442 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167442 9141_ $$y2021
000167442 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL LUNG CANCER R : 2018$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-05
000167442 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-05
000167442 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000167442 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000167442 980__ $$ajournal
000167442 980__ $$aVDB
000167442 980__ $$aI:(DE-He78)C020-20160331
000167442 980__ $$aI:(DE-He78)E010-20160331
000167442 980__ $$aUNRESTRICTED